huCART-meso cells

BIOLOGICAL4 trials

Conditions

Breast CancerCancer of the PancreasFallopian Tube CancerLung AdenocarcinomaMesothelioma PeritoneumMesotheliomas PleuralOvarian CancerPancreatic Cancer

Phase 1

CAR T Cells in Mesothelin Expressing Cancers

CompletedNCT03054298

University of PennsylvaniaFallopian Tube Cancer, Lung Adenocarcinoma, Mesothelioma Peritoneum +3

Start: 2017-04-06End: 2024-07-30Updated: 2025-04-29

CAR T Cell Immunotherapy for Pancreatic Cancer

TerminatedNCT03323944

University of PennsylvaniaCancer of the Pancreas, Pancreatic Cancer

Start: 2017-09-15End: 2025-02-20Updated: 2026-01-30

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

Active, not recruitingNCT05057715

University of PennsylvaniaPancreatic Cancer, Serous Ovarian Cancer

Start: 2022-03-02End: 2038-09-01Updated: 2026-07-13

CAR T Cells in Mesothelin-Expressing Breast Cancer

TerminatedNCT05623488

University of PennsylvaniaBreast Cancer

Start: 2023-02-06End: 2025-04-07Updated: 2025-08-12

Journal of Clinical Oncology2026-05-28

Emerging landscape of CAR T-cell therapy in gastrointestinal malignancies: A systematic review of clinical trials.

Journal of Clinical Oncology2026-01-10

Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer.

2025-08-183 citations

Abstract 5255: Systemic immunosuppression in pancreatic cancer

Cancer Research2025-04-21

Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies

Blood2023-11-022 citations

671 Phase 1 trial of human chimeric antigen receptor modified T cells (huCART-meso) administered in combination with oncolytic virus VCN-01 in patients with pancreatic and ovarian cancer

Regular and Young Investigator Award Abstracts2023-10-311 citations

The Role of Asbestos in Global Malignant Mesothelioma

Oncology Times2023-01-03

huCART-meso cells

Sponsors

Conditions

Phase 1

Related Papers